Vanda Pharmaceuticals Announces Presentations at DDW 2022

WASHINGTON, May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022.

The following will be presented:

May 21, 2022

Presentation Title: "THE ROLE OF M1 TO M2 MACROPHAGE POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS PERSPECTIVE"
Abstract Number: 3752409
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Plenary Session
Session Title: Late-Breaking Basic Science Abstract Plenary
Session Time: 2:00 PM to 3:30 PM PDT
Presentation Time: 2:15 PM to 2:30 PM PDT

May 23, 2022

Presentation Title: "ENRICHMENT OF PATIENTS WITH EHLERS DANLOS SYNDROME IN IDIOPATHIC GASTROPARESIS ? A GENE SET ENRICHMENT ANALYSIS"
Abstract Number: 3696881
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Poster Session
Session Title: Cell Biology, Biochemistry and Integrative Physiology
Session Time: 12:30 PM to 1:30 PM PDT

For more information on DDW 2022, please refer to https://ddw.org/.

About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected] 

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected] 

SOURCE Vanda Pharmaceuticals Inc.